Cemal Nuri Ercin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cemal Nuri Ercin has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Teoman Dogru
Department of Gastroenterology, Gulhane Military Medical Faculty, Ankara, Turkey
34 shared publicationsSerkan Tapan
Medical Biochemistry , Gulhane School of Medicine, Ankara, Turkey
24 shared publications- Alper Sonmez
Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey
20 shared publications - Halil Genc
Department of Gastroenterology, Gulhane School of Medicine, Ankara, Turkey
18 shared publications - Ilker Tasci
Department of Internal Medicine, Ufuk University, Ankara, Türkiye
14 shared publications Muammer Kara
Department of Gastroenterology, GATA Haydarpasa Training Hospital, Istanbul bBiochemistry Laboratory, Ankara Mevki Military Hospital, Anittepe Dispensary Departments of cGastroenterology dPathology eEndocrinology and Metabolism, Gulhane School of Medicine, Ankara fDepartment of Gastroenterology, Izmir Military Hospital, Izmir gBiochemistry Laboratory, Adana Military Hospital, Adana, Turkey
13 shared publications
Latest Publications
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (2) , 167-170
Peritonitis due to brucellosis in a patient newly diagnosed with liver cirrhosis complicated by ascites: A case report and literature review
Brucellosis is a common zoonotic disease with a wide variety of clinical manifestations. Spontaneous bacterial peritonitis (SBP) is a rare form among them. Here, we present the case of a 63-year-old woman with newly diagnosed liver cirrhosis complicated with ascites and diagnosed as spontaneous bacterial peritonitis with Brucella spp. growth in culture, and the literature is reviewed.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (2) , 167-170
Peritonitis due to brucellosis in a patient newly diagnosed with liver cirrhosis complicated by ascites: A case report and literature review
Brucellosis is a common zoonotic disease with a wide variety of clinical manifestations. Spontaneous bacterial peritonitis (SBP) is a rare form among them. Here, we present the case of a 63-year-old woman with newly diagnosed liver cirrhosis complicated with ascites and diagnosed as spontaneous bacterial peritonitis with Brucella spp. growth in culture, and the literature is reviewed.
- Open Access
- 1 January 2024
- Published by Kare Publishing in Hepatology Forum
- Vol. 5 (2) , 61-62
New classification of Drug Induced Liver Injury (DILI) in AASLD Guidance: What is next?
- 1 January 2024
- Published by Kare Publishing in Hepatology Forum
- Vol. 5 (2) , 61-62
Open AccessNew classification of Drug Induced Liver Injury (DILI) in AASLD Guidance: What is next?
- Open Access
- 29 July 2023
- Published by Dahiliye uzmanlari dernegi (DAHUDER) in DAHUDER Medical Journal
- Vol. 3 (3) , 91-96
The relationship of serum bilirubin level with histopathological parameters in patients with nonalcoholic fatty liver disease
Objectives: Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease and is known as a part of metabolic syndrome (MetS), and the role of bilirubin in the pathogenesis of NAFLD is unclear. This study aimed to evaluate the relationship between bilirubin levels and histopathological findings in patients with NAFLD having no confounding factors such as morbid obesity, diabetes mellitus (DM), and hypertension. Methods: A retrospective analysis of clinical and laboratory data of patients with biopsy-proven NAFLD was performed. The relationship between the bilirubin levels and histopathologic findings was evaluated. Results: The subjects in the nonalcoholic steatohepatitis (NASH) group had greater AST (p < 0.001) and ALT (p < 0.001) levels than the non-NASH group. We found no difference between NASH and non-NASH groups regarding bilirubin levels. The levels of AST (p = 0.001), ALT (p = 0.011), insulin (p = 0.029), and HOMA-IR index (p = 0.027) were higher in fibrosis group comparing non-fibrosis group. However, bilirubin levels were not different comparing the fibrosis and non-fibrosis group. We couldn’t find any relation between bilirubin levels and other parameters in correlation analysis. Conclusion: We couldn’t find any relation between the bilirubin levels and histopathological findings of the patient with NAFLD having no confounding factors such as morbid obesity, DM, and hypertension. The difference, shown in the other studies, may be the effect of other diseases related to MetS.
- 29 July 2023
- Published by Dahiliye uzmanlari dernegi (DAHUDER) in DAHUDER Medical Journal
- Vol. 3 (3) , 91-96
Open AccessThe relationship of serum bilirubin level with histopathological parameters in patients with nonalcoholic fatty liver disease
Objectives: Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease and is known as a part of metabolic syndrome (MetS), and the role of bilirubin in the pathogenesis of NAFLD is unclear. This study aimed to evaluate the relationship between bilirubin levels and histopathological findings in patients with NAFLD having no confounding factors such as morbid obesity, diabetes mellitus (DM), and hypertension. Methods: A retrospective analysis of clinical and laboratory data of patients with biopsy-proven NAFLD was performed. The relationship between the bilirubin levels and histopathologic findings was evaluated. Results: The subjects in the nonalcoholic steatohepatitis (NASH) group had greater AST (p < 0.001) and ALT (p < 0.001) levels than the non-NASH group. We found no difference between NASH and non-NASH groups regarding bilirubin levels. The levels of AST (p = 0.001), ALT (p = 0.011), insulin (p = 0.029), and HOMA-IR index (p = 0.027) were higher in fibrosis group comparing non-fibrosis group. However, bilirubin levels were not different comparing the fibrosis and non-fibrosis group. We couldn’t find any relation between bilirubin levels and other parameters in correlation analysis. Conclusion: We couldn’t find any relation between the bilirubin levels and histopathological findings of the patient with NAFLD having no confounding factors such as morbid obesity, DM, and hypertension. The difference, shown in the other studies, may be the effect of other diseases related to MetS.
- 7 September 2022
- Published by Galenos Yayinevi in Gulhane Medical Journal
- Vol. 64 (3) , 240-247
The relationship of atherogenic index of plasma with endothelial dysfunction biomarkers in patients with metabolic associated fatty liver disease
- 7 September 2022
- Published by Galenos Yayinevi in Gulhane Medical Journal
- Vol. 64 (3) , 240-247
The relationship of atherogenic index of plasma with endothelial dysfunction biomarkers in patients with metabolic associated fatty liver disease
- Open Access
- 28 June 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (7) , 425
Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease
Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32); non-NASH (n = 18)] and 30 healthy controls were included. Plasma betatrophin was measured by ELISA method. Insulin sensitivity was assessed by HOMA-IR index. Histological features were scored by the semi quantitative classification and combined as the NAFLD activity score (NAS). Betatrophin levels in the non-NASH group were significantly higher than the controls. Betatrophin was positively correlated to the age, waist circumference, total cholesterol, triglycerides, LDL cholesterol, glucose, insulin, HOMA-IR index and gamma glutamyl transpeptidase levels, and negatively correlated to the steatosis and NAS. In the stepwise linear regression analysis, the triglyceride (β = 0.457, p < 0.001), glucose (β = 0.281, p = 0.02) and NAS (β = −0.260, p = 0.03) were the independent determinants of betatrophin. Betatrophin levels are higher in the early stages of NAFLD and tend to decrease when the disease progresses. This could be an important preliminary mechanistic finding to explain the increased frequency of glucose intolerance during the course of NAFLD.
- 28 June 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (7) , 425
Open AccessBetatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease
Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32); non-NASH (n = 18)] and 30 healthy controls were included. Plasma betatrophin was measured by ELISA method. Insulin sensitivity was assessed by HOMA-IR index. Histological features were scored by the semi quantitative classification and combined as the NAFLD activity score (NAS). Betatrophin levels in the non-NASH group were significantly higher than the controls. Betatrophin was positively correlated to the age, waist circumference, total cholesterol, triglycerides, LDL cholesterol, glucose, insulin, HOMA-IR index and gamma glutamyl transpeptidase levels, and negatively correlated to the steatosis and NAS. In the stepwise linear regression analysis, the triglyceride (β = 0.457, p < 0.001), glucose (β = 0.281, p = 0.02) and NAS (β = −0.260, p = 0.03) were the independent determinants of betatrophin. Betatrophin levels are higher in the early stages of NAFLD and tend to decrease when the disease progresses. This could be an important preliminary mechanistic finding to explain the increased frequency of glucose intolerance during the course of NAFLD.
- 30 August 2020
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- Vol. 28 (2) , 42-46
Kolorektal premalign polipler ile mide premalign lezyonları arasındaki ilişki
Giriş ve Amaç: Kolorektal premalign lezyonların en önemlisi poliplerdir. Poliplerin histopatolojisi ve boyutlarına göre malignite riski değişmektedir. Ayrıca mide mukozasında displazi, atrofi, intestinal metaplazi, polip ve Helicobacter pylori gibi faktörler de mide için prekanseröz durumlardır. Çalışmamızın amacı; kolorektal poliplerin yerleşimi, boyutu, sayısı ve patolojisi ile midenin premalign lezyonları arasındaki ilişkiyi ortaya koymaktır. Gereç ve Yöntem: Çalışmamız Ekim 2016 ile Ekim 2019 tarihleri arasında 18 yaş ve üzeri hastalara aynı gün yapılan özofagogastroduodenoskopi ve kolonoskopi verilerinin değerlendirildiği retrospektif bir çalışmadır. İnflamatuvar barsak hastalığı olan, mide kanseri ve kolorektal kanser tanısı alan, mide biyopsisi alınmayan, barsak temizliği yetersiz olan ve işlemi tamamlayamayan hastalar çalışmaya dahil edilmemiştir. Bulgular: İki yüz elli yedi hastanın %58.0’i erkek ve %80.9’u 50 yaşın üzerindeydi. Kolorektal poliplerin çoğunluğu distal yerleşimliydi (%59.1). İleri adenomatöz polip (İAP) sıklığı %24.9 olup ileri adenomatöz polip varlığı ile 50 yaş altı ve üzeri hastalar arasında ve cinsiyete göre istatistiksel fark yoktu (p: 0.659 ve p: 0.747). Helicobacter pylori, atrofi, intestinal metaplazi, displazi ve polip gibi midenin premalign lezyonları ile ileri adenomatöz polip arasında istatistiksel olarak anlamlı bir ilişki gözlenmedi (p: 0.301 ). Sonuç: Kolorektal poliplerin yeri, sayısı ve ileri adenomatöz polip ile premalign mide lezyonları arasında ilişki saptanmamıştır.
- 30 August 2020
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- Vol. 28 (2) , 42-46
Kolorektal premalign polipler ile mide premalign lezyonları arasındaki ilişki
Giriş ve Amaç: Kolorektal premalign lezyonların en önemlisi poliplerdir. Poliplerin histopatolojisi ve boyutlarına göre malignite riski değişmektedir. Ayrıca mide mukozasında displazi, atrofi, intestinal metaplazi, polip ve Helicobacter pylori gibi faktörler de mide için prekanseröz durumlardır. Çalışmamızın amacı; kolorektal poliplerin yerleşimi, boyutu, sayısı ve patolojisi ile midenin premalign lezyonları arasındaki ilişkiyi ortaya koymaktır. Gereç ve Yöntem: Çalışmamız Ekim 2016 ile Ekim 2019 tarihleri arasında 18 yaş ve üzeri hastalara aynı gün yapılan özofagogastroduodenoskopi ve kolonoskopi verilerinin değerlendirildiği retrospektif bir çalışmadır. İnflamatuvar barsak hastalığı olan, mide kanseri ve kolorektal kanser tanısı alan, mide biyopsisi alınmayan, barsak temizliği yetersiz olan ve işlemi tamamlayamayan hastalar çalışmaya dahil edilmemiştir. Bulgular: İki yüz elli yedi hastanın %58.0’i erkek ve %80.9’u 50 yaşın üzerindeydi. Kolorektal poliplerin çoğunluğu distal yerleşimliydi (%59.1). İleri adenomatöz polip (İAP) sıklığı %24.9 olup ileri adenomatöz polip varlığı ile 50 yaş altı ve üzeri hastalar arasında ve cinsiyete göre istatistiksel fark yoktu (p: 0.659 ve p: 0.747). Helicobacter pylori, atrofi, intestinal metaplazi, displazi ve polip gibi midenin premalign lezyonları ile ileri adenomatöz polip arasında istatistiksel olarak anlamlı bir ilişki gözlenmedi (p: 0.301 ). Sonuç: Kolorektal poliplerin yeri, sayısı ve ileri adenomatöz polip ile premalign mide lezyonları arasında ilişki saptanmamıştır.
- 15 May 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (5) , 348-355
The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel acute infectious disease that has rapidly reached staggering pandemic proportions. This document addresses gastroenterologists, hepatologists, liver transplant specialist and health-care professionals working in the field of liver diseases and liver transplantation. It has been composed based on a limited number of publications, recommendations of national and international liver and organ transplantation societies, and COVID-19 patient experiences around the world. The purpose of this document is to provide information addressing questions and concerns about COVID-19, to reveal the effects of the novel disease on patients with chronic liver disease and liver transplant recipients, and to share information about the ways in which this pandemic will affect clinical practices. We, the Turkish Association for the Study of the Liver (TASL), would like to remind you that this text could actually be not a practical guide. It is imperative to act according to the standards set by health-care institutions and the Ministry of Health, Republic of Turkey.
- 15 May 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (5) , 348-355
The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel acute infectious disease that has rapidly reached staggering pandemic proportions. This document addresses gastroenterologists, hepatologists, liver transplant specialist and health-care professionals working in the field of liver diseases and liver transplantation. It has been composed based on a limited number of publications, recommendations of national and international liver and organ transplantation societies, and COVID-19 patient experiences around the world. The purpose of this document is to provide information addressing questions and concerns about COVID-19, to reveal the effects of the novel disease on patients with chronic liver disease and liver transplant recipients, and to share information about the ways in which this pandemic will affect clinical practices. We, the Turkish Association for the Study of the Liver (TASL), would like to remind you that this text could actually be not a practical guide. It is imperative to act according to the standards set by health-care institutions and the Ministry of Health, Republic of Turkey.
- 29 April 2019
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 19 (1) , 25-30
The Relationship Between Histopathological Stages of Liver Fibrosis and Albumin–Bilirubin Score in Chronic Hepatitis C Infection
Giriş ve Amaç: Karaciğer fibrozunu değerlendirmek için birçok invaziv olmayan biyokimyasal indeksler geliştirilmiştir. Bu çalışmada allbümin-bilirübin skorunun kronik hepatit C virüs enfeksiyonunda gelişen karaciğer fibrozunun tahmininde karaciğer biyopsisine alternatif bir tanı yöntemi olup olamayacağının değerlendirilmesi ve diğer biyokimyasal belirteçler olan fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeksi ile karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Yaş aralığı 20 ile 82 arasında değişen, karaciğer biyopsisi yapılmış, 27’si erkek ve 11’i kadın toplam 38 kronik hepatit C virüs enfeksiyonlu hasta değerlendirildi. Albümin-bilirübin, fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skorları hesaplandı. Albümin-bilirübin skorunun fibrozis evre >2 ve >4’ü ayırt etme yeteneği ROC analizi ile değerlendirildi ve fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skoru ile karşılaştırıldı. Bulgular: Albümin-bilirübin skorunun fibrozis evre >2 ve fibrozis evre ≥4 tanısı için ROC eğrisi altında kalan alan sırasıyla 0.767 (95% Cl: 0.564-0.969) ve 0.956 (95% Cl: 0.889-1.000) bulunurken, fibrozis-4 için 0.863 (95% Cl: 0.714-1.000) ve 0.926 (95% Cl: 0.833-1.000), aspartat aminotransferaz/ trombosit oran indeks skoru için 0.667 (95% Cl: 0.450-0.884) ve 0.640 (95% Cl: 0.378-0.901) idi. Sonuç: Bulgulara göre albümin-bilirübin skorunun fibrozis evre >2 ve ileri karaciğer fibrozunu (fibrozis evre >4) tahmin edebileceği değerlendirilmiştir. Albümin-bilirübin skorunun fibrozis tahminindeki performansı, aspartat aminotransferaz/trombosit oran indeks skoru ve fibrozis-4 ile karşılaştırıldığında sonuçların benzer olduğu ancak fibrozis evre >2 tahmininde fibrozis-4’ün, fibrozis evre ≥4’de ise aspartat aminotransferaz/ trombosit oran indeks skorunun daha güvenilir sonuç verdiği değerlendirilmiştir.
- 29 April 2019
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 19 (1) , 25-30
The Relationship Between Histopathological Stages of Liver Fibrosis and Albumin–Bilirubin Score in Chronic Hepatitis C Infection
Giriş ve Amaç: Karaciğer fibrozunu değerlendirmek için birçok invaziv olmayan biyokimyasal indeksler geliştirilmiştir. Bu çalışmada allbümin-bilirübin skorunun kronik hepatit C virüs enfeksiyonunda gelişen karaciğer fibrozunun tahmininde karaciğer biyopsisine alternatif bir tanı yöntemi olup olamayacağının değerlendirilmesi ve diğer biyokimyasal belirteçler olan fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeksi ile karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Yaş aralığı 20 ile 82 arasında değişen, karaciğer biyopsisi yapılmış, 27’si erkek ve 11’i kadın toplam 38 kronik hepatit C virüs enfeksiyonlu hasta değerlendirildi. Albümin-bilirübin, fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skorları hesaplandı. Albümin-bilirübin skorunun fibrozis evre >2 ve >4’ü ayırt etme yeteneği ROC analizi ile değerlendirildi ve fibrozis-4 ve aspartat aminotransferaz/trombosit oran indeks skoru ile karşılaştırıldı. Bulgular: Albümin-bilirübin skorunun fibrozis evre >2 ve fibrozis evre ≥4 tanısı için ROC eğrisi altında kalan alan sırasıyla 0.767 (95% Cl: 0.564-0.969) ve 0.956 (95% Cl: 0.889-1.000) bulunurken, fibrozis-4 için 0.863 (95% Cl: 0.714-1.000) ve 0.926 (95% Cl: 0.833-1.000), aspartat aminotransferaz/ trombosit oran indeks skoru için 0.667 (95% Cl: 0.450-0.884) ve 0.640 (95% Cl: 0.378-0.901) idi. Sonuç: Bulgulara göre albümin-bilirübin skorunun fibrozis evre >2 ve ileri karaciğer fibrozunu (fibrozis evre >4) tahmin edebileceği değerlendirilmiştir. Albümin-bilirübin skorunun fibrozis tahminindeki performansı, aspartat aminotransferaz/trombosit oran indeks skoru ve fibrozis-4 ile karşılaştırıldığında sonuçların benzer olduğu ancak fibrozis evre >2 tahmininde fibrozis-4’ün, fibrozis evre ≥4’de ise aspartat aminotransferaz/ trombosit oran indeks skorunun daha güvenilir sonuç verdiği değerlendirilmiştir.
- 20 June 2017
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 48 (3) , 281
Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience
- 20 June 2017
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 48 (3) , 281
Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience
- 1 October 2016
- Vol. 20 (20) , 4305-4312
Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease.
Pentraxin-3 (PTX-3) is an acute-phase protein belonging to the PTX family. It has been reported that PTX-3 is significantly associated with obesity, metabolic syndrome, and cardiovascular diseases (CVD). Non-alcoholic fatty liver disease (NAFLD) is strongly associated with atherosclerosis and CVD. In this study, we aimed to investigate the relationship of PTX-3 with circulating markers of endothelial dysfunction and atherosclerosis in patients with NAFLD. Seventy patients with biopsy-proven NAFLD and seventy healthy controls were enrolled in the study. Plasma asymmetric dimethylarginine (ADMA), adiponectin, and PTX-3 levels were determined using enzyme-linked immunosorbent assay (ELISA). High-sensitivity C-reactive protein (hsCRP) serum levels were measured with the immunoturbidimetric assay. Insulin resistance was estimated using the HOMA-IR index. PTX-3 and hsCRP levels were higher and adiponectin levels were lower in the NAFLD group compared to the healthy controls (p < 0.001 for all). In correlation analysis, a significant association was observed between PTX-3 and ADMA levels (r = 0.423, p < 0.001). Our study demonstrated for the first time that increased circulating PTX-3 is strongly associated with endothelial dysfunction in subjects with NAFLD. However, large prospective studies are needed to establish the independent predictive value of PTX-3 for CVD endpoints in this clinically relevant condition.
- 1 October 2016
- Vol. 20 (20) , 4305-4312
Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease.
Pentraxin-3 (PTX-3) is an acute-phase protein belonging to the PTX family. It has been reported that PTX-3 is significantly associated with obesity, metabolic syndrome, and cardiovascular diseases (CVD). Non-alcoholic fatty liver disease (NAFLD) is strongly associated with atherosclerosis and CVD. In this study, we aimed to investigate the relationship of PTX-3 with circulating markers of endothelial dysfunction and atherosclerosis in patients with NAFLD. Seventy patients with biopsy-proven NAFLD and seventy healthy controls were enrolled in the study. Plasma asymmetric dimethylarginine (ADMA), adiponectin, and PTX-3 levels were determined using enzyme-linked immunosorbent assay (ELISA). High-sensitivity C-reactive protein (hsCRP) serum levels were measured with the immunoturbidimetric assay. Insulin resistance was estimated using the HOMA-IR index. PTX-3 and hsCRP levels were higher and adiponectin levels were lower in the NAFLD group compared to the healthy controls (p < 0.001 for all). In correlation analysis, a significant association was observed between PTX-3 and ADMA levels (r = 0.423, p < 0.001). Our study demonstrated for the first time that increased circulating PTX-3 is strongly associated with endothelial dysfunction in subjects with NAFLD. However, large prospective studies are needed to establish the independent predictive value of PTX-3 for CVD endpoints in this clinically relevant condition.